Fosinopril drug data and news

---

Glenmark close to diabetic deals with global firms  Oct 3, 2005
The company also entered into an exclusive licensing agreement with InvaGen Inc for marketing its anti-hypertensive agent Fosinopril Sodium oral tablets in the ... - Business Standard,

Glenmark gets US FDA approval for its Goa facility  Oct 3, 2005
InvaGen Inc. for marketing its anti-hypertensive agent, Fosinopril Sodium oral tablets [Monopril(r)], for the US market. Glenmark ... - Myiris.com,

Glenmark to Sell Blood-Pressure Drug in the US Market  Aug 12, 2005
Mumbai based Glenmark Pharmaceuticals has started exporting to the US, the chemical equivalent of fosinopril sodium oral tablets used to lower blood pressure ... - Express Pharma Pulse,

Glenmark partners with InvaGen for Fosinopril tabs  Jul 27, 2005
Pharmaceuticals wholly owned US subsidiary, Glenmark Pharmaceuticals (USA), has made a exclusive marketing tie-up with InvaGen for its Fosinopril Sodium oral ... - Business Standard

Glenmark starts sale of hypertensive drug in US  Jul 28, 2005
Pharmaceuticals Ltd. has commenced shipment of its generic equivalent Fosinopril Sodium oral tablets (Monopril) for the US market. The ... - India Infoline.com

Glenmark launches third generic product  Jul 28, 2005
Glenmark Pharmaceuticals Inc., USA [GPI], a wholly owned subsidiary of the Company, has commenced shipment of its generic equivalent Fosinopril Sodium oral ... - Sify

Glenmark launches anti-hypertensive drug  Jul 29, 2005
NEW DELHI: Glenmark Pharmaceuticals Ltd on Thursday said it had launched the generic equivalent of the anti-hypertensive drug, Fosinopril Sodium oral tablets ... - Economic Times

Glenmark to sell InvaGen drug in US market  Jul 26, 2005
Pharmaceuticals, the US subsidiary of Glenmark Pharmaceuticals, has entered into a licensing agreement with InvaGen for the anti-hypertensive drug, fosinopril. ... - Economic Times

Eon Labs Reports Sales and Net Income for the First Quarter of ...  Apr 28, 2005
...first quarter of 2005, as well as, the sales of products that were introduced subsequent to the first quarter of 2004, including Fosinopril Sodium, Citalopram ... - Business Wire,

Eon Labs Reports Sales and Net Income for the First Quarter of ...  29 Apr 2005
...first quarter of 2005, as well as, the sales of products that were introduced subsequent to the first quarter of 2004, including Fosinopril Sodium, Citalopram ... - Business Wire

Hemispherx Biopharma's Investigational Drug Increases Physical ...  Apr 11, 2005
For example, in CHF: Fosinopril (6.7% improvement), Captopril (6.2%), Ranolazine (6.5%) and Ranolazine (5.7%); in AI, Tracleer (10.6% improvement), Remodulin ... - Business Wire,

Eon Labs Reports Sales and Earnings for the Fourth Quarter and ...  Mar 1, 2005
...to the fourth quarter ended December 31, 2003 that also contributed to the increase in net sales included Metolazone, Citalopram, Fosinopril and Cilostazol. ... - PharmaLive.com (press release),

BCBSNC Launches New Prescription Drug Savings Initiative  Feb 17, 2005
Drugs to Treat High Blood Pressure) benazepril (generic Lotensin) captopril (generic Capoten) enalapril (generic Vasotec) fosinopril (generic Monopril ... - PR Newswire (press release)

Diuretics: Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium. The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION.)

Potassium Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics. Potassium-sparing diuretics (spironolactone, amiloride,triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution, and the patient's serum potassium should be monitored frequently.

Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.

Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril. Therefore, if concomitant administration of these agents is indicated, dosing should be separated by 2 hours.

Other: Neither fosinopril sodium nor its metabolites have been found to interact with food. In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs. In a study with concomitant administration of aspirin and fosinopril sodium, the bioavailability of unbound fosinoprilat was not altered.

In a pharmacokinetic interaction study with warfarin, bioavailability parameters, the degree of protein binding, and the anticoagulant effect (measured by prothrombin time) of warfarin were not significantly changed.

Drug/Laboratory Test Interaction

Fosinopril may cause a false low measurement of serum digoxin levels with the Digi- Tab® RIA Kit for Digoxin. Other kits, such as the Coat-A-Count® RIA Kit, may be used.